Sun Pharma Q2 profit rises 10.5% to ₹2,262 cr; revenue up 13%
Sun Pharma MD Dilip Shanghvi says in Q2, Sun Pharma recorded double-digit topline growth and strong margins, driven by market share gain in India, and sustained ramp-up of global specialty biz.
Suzlon, a renewable ‘loan’ company is back to raising funds; should you invest?
It seems the previous capital raised by Suzlon has been blown away and the company is going back to its existing shareholders for raising fresh capital worth ₹1,200 crore through a rights issue.
Covid catapults Cyrus Poonawalla to richest in pharma
Cyrus Soli Poonawalla’s Serum Institute of India made the most of the country’s demand for vaccines.
Shanghvi's Silent 'Sun' Rise
Acquisitions and product focus make Shanghvi India's wealthiest drug maker.
AIRA Matrix — Dilip Shanghvi’s shot at drug discovery via AI
The company, set up and funded by Sun Pharma founder and MD Dilip Shanghvi’s family office, is focusing on AI-led pharma research and development, even offering tech tools to the industry for R&D.
US business remains Sun Pharma’s weak spot
US sales have dropped to less than a third of overall revenue from nearly half five years ago and profits have taken a beating despite cost synergies after the acquisition of Ranbaxy Laboratories.